HC Wainwright & Co. Reiterates Buy on Praxis Precision Medicine, Maintains $120 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Praxis Precision Medicine (NASDAQ:PRAX) and maintained a price target of $120.
September 10, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Douglas Tsao has reiterated a Buy rating for Praxis Precision Medicine and maintained a price target of $120, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $120 price target by a reputable analyst suggests positive sentiment and confidence in Praxis Precision Medicine's future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100